טוען...
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90–100% of malignant mature B-lymphocyte lineage. The first Pha...
שמור ב:
| הוצא לאור ב: | Immunotherapy |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Future Medicine Ltd
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5618942/ https://ncbi.nlm.nih.gov/pubmed/26780449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt.15.108 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|